ADVISORY/Mark the Date: Tuesday, November 10, Press Briefing and Dinner At AHA.

--(BW HealthWire)--

THE NEW EMERGING STANDARD OF CARE IN

ACUTE CORONARY SYNDROMES: TIMI11B AND BEYOND

WHAT: Results of the TIMI11B trial confirm that a new direction in the

treatment of acute coronary syndromes (ACS), namely angina and

non-Q-wave heart attack, is emerging to replace the current

standard of care. On November 10, for the first time in the U.S.,

the results of the 3,910 patient TIMI11B study will be presented

at the American Heart Association 71st Scientific Sessions. Join

the lead investigator of TIMI11B, Elliott Antman, MD, and his

colleagues as they discuss this trial and other global studies

that are likely to have an impact on the practice of cardiology

in the management of ACS around the world.

WHO: Elliott M. Antman, MD, Brigham and Women's Hospital, Harvard

Medical School

Topic: TIMI11B results

Shaun Goodman, MD, St. Michael's Hospital, University of Toronto 

Topic: ESSENCE at one year

Sumita Paul, MD, and Robert Leadley, PhD, Rhone-Poulenc Rorer

Topics: Current cardiovascular trials with enoxaparin -- The NICE-4

trial and other combinations, e.g., enoxaparin and GP IIB/IIIA

inhibitors

WHERE: THE WYNDHAM ANATOLE HOTEL, MILAN ROOM (TOWER MEZZANINE)

2201 Stemmons Freeway

Dallas, TX 75207

WHEN: TUESDAY, NOVEMBER 10, 1998

6:30 p.m. Dinner

7:00 p.m. Presentations and Q&A

TRANSPORTATION: Will depart curbside (Marilla Street) at the Dallas

Convention Center at 6:00 p.m.

Please RSVP to Kathie Schoff at MCS, [phone], or in Dallas, Kristen Supchak at the Doubletree Campbell Center, [phone].

Sponsored by Brigham and Women's Hospital and Rhone-Poulenc Rorer, Inc.